Some great press around on the general efficacy of CBD against bacteria and superbugs. (in light of antibiotic resistant bacteria). This idea has been around for a while but more evidence that CBD as a medicine is not only here to stay but emerging as a super class of medical treatment breakthrough applications. The "green rush" for cannabis has taken a while but is in full swing now.
Mental health, where there has been very little in the way of advancement in treatments for a long time, is being seen like CBD but vastly accelerated as a new "rush" to better and more effective health care solutions. (according to Bloomberg's recent article on disruptions to the $70 Billion US health market) Not only as a class of medicine but in treatment protocol development.
IHL is the only globally stock exchange listed company that has an advanced product development suite in both CBD and Psychedelics clinical research. Not forgetting the growing CBD Oil business - which is constantly finding new applications, such as anti -bacterial efficacy.
Very exciting times for IHL with OSA (Obstructive sleep apnoea, TBI (Traumatic brain injury and SAARDS (Sepsis associated ARDS) CBD R&D. All multi billion dollar industries. Key advantage of course is that these treatments are novel and have global intellectual property value. IHL will IMO also benefit greatly from the generic efficacies of CBD, such as anti bacterial, via their growing oil sales business. Best of both worlds. Great time to be an investor!
Add to My Watchlist
What is My Watchlist?